Phase Ib dose de-escalating trial of NB-1001 in patients with short bowel syndrome

Trial Profile

Phase Ib dose de-escalating trial of NB-1001 in patients with short bowel syndrome

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs NB 1001 (Primary)
  • Indications Short bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 According to a Naia Limited media release, company has received Clinical Trial Authorisation ("CTA") from the Medicine and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a clinical trial of NB 1001, in adult patients with Short Bowel Syndrome.
    • 03 Apr 2017 According to a Naia Limited media release, Dr. Pimentel will be principal investigator for this trial.
    • 30 Nov 2016 According to a Naia Limited, the company has submitted an investigational New Drug (IND) application to the US FDA to initiate this trial for NB 1001.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top